Italian Association for Clinical Microbiology (IT-AMCLI)
The Society aims to offer professionals an important support on their daily work, trough meetings, courses and congresses an update on most important Microbiological issues ; the Society gives also the possibility to have grants with FEMS for educational purposes and trough the web the possibility to use any information coming from European and International Societies (FEMS, ESCMID, NCCLS, IUMS) AMCLI supports with its member expertise the European microbiology community (ECDC etc)
Membership location: each member of the Society has both national and regional membership; society supports the subscription of delegate to International Societies
Membership scope: AMCLI is a scientific Society finalized to the promotion of Clinical Microbiology in Italy and Europe through affiliation to European Microbiology Societies; study groups support nosocomial infections,
antibiotics policy, parasitology, mycology, mycobacteriology, pregnancy infections, transplant patients microbiology, Sexually Transmitted Infections. AMCLI organizes a National Annual Congress and several thematic courses or meetings during the year. Members in AMCLI work as microbiologists in Public Hospitals, Universities, National Institutions where they contribute to the benefit of public health. Microbiology research is performed in University. The Society publishes thematic educational books and has an online journal printed every 3 months in English. AMCLI organizes a Summer School for Microbiology; technicians to improve their professional development.
|Membership type||fee (currency)||notes|
|Full member||65 (€)||Membership requires involvement in Microbiology work in Hospitals, Universities, Institutions. Specialization doctors benefit of a special fare or of no fare for some courses or meetings.|
How to join
Contact point: Membership Officer
Dr Pierangelo Clerici
Contact point: FEMS Delegate
Member of FEMS since 1996
The aim of this study was to determine whether in vitro induced erythromycin resistance facilitates the cross-resistance to the novel fluoroketolide, solithromycin, in Staphylococcus aureus. Long-term exposure of erythromycin results in resistance to ketolides in S. aureus through drug binding site mutations. These results demonstrate that since erythromycin has been used clinically for a long time, it is necessary to carefully evaluate the rewards and risks when prescribing solithromycin for the treatment of infectious diseases.